Clinical Ophthalmology (Nov 2022)
Pulsed Light Therapy in the Management of Dry Eye Disease: Current Perspectives
Abstract
Bruno Barbosa Ribeiro,1 Ana Marta,1,2 João Ponces Ramalhão,1 João Heitor Marques,1 Irene Barbosa1,2 1Centro Hospitalar Universitário do Porto’s Department of Ophthalmology (CHUPorto), Oporto, Portugal; 2Instituto de Ciências Biomédicas Abel Salazar (ICBAS), Oporto, PortugalCorrespondence: Ana Marta, Centro Hospitalar Universitário do Porto’s Department of Ophthalmology, Largo do Prof. Abel Salazar, Oporto, 4099-001, Portugal, Tel +351 222077500, Email [email protected]: To review the indications and efficacy of Intense Pulsed Light (IPL) application in the treatment of Meibomian Gland Dysfunction (MGD). Its main purpose is to describe its physiology, efficacy, indications, and adverse effects.Patients and Methods: A two database (PubMed, EMBASE) search was performed from July 2017 to July 2022 using the MeSH terms (“Intense Pulsed Light” AND (“Meibomian Gland Dysfunction” OR “Dry Eye”). We included randomized studies and systematic reviews with meta-analysis. Exclusion criteria were non-randomized trials, studies enrolling non-MGD dry eye disease, and other works older than 5 years.Results: Current literature shows that IPL is an effective and safe treatment modality for severe dry eye. Available evidence shows improvement of symptoms and objective indicators, such as noninvasive breakup time, thickness of lipid layer, and Schirmer test. However, our review concluded that the beneficial effects of IPL may lose some efficacy at 6-months after the initial session, and subsequent sessions may be required. Thus, IPL treatment should not be considered as first-line therapy for MGD but instead as an adjuvant option to the standard of care. The optimal treatment modality remains unknown and should be tailored according to each patient’s phenotype, clinician’s experience, and available technology. There is evidence that IPL treatment may down-regulate pro-inflammatory markers (such as interleukin (IL) 6, IL17a, IL-1) and Prostaglandin E2 (PGE2).Conclusion: MGD is a multifactorial disease and IPL treatment seems a promising treatment modality. Despite this, more evidence is needed to study its benefits – since this is an emerging technology, it is expected an increase in comparative studies in the following years, with longer follow-up periods, which may enable more precise conclusions about this treatment modality.Keywords: dry eye disease, meibomian gland dysfunction, intense pulsed light, low-level light therapy, near-infrared light therapy, ocular surface disease index
